# OrphanCure Full Pipeline Report: repodb_0f5d00f3cf88c277

- Drug: Prednisolone
- Disease: Bacterial keratitis
- Mode: no_verifier
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "No literature was retrieved to support or refute the repurposing of prednisolone for autosomal dominant keratitis-ichthyosis-hearing loss syndrome. Therefore, the hypothesis is currently unsupported.",
      "evidence_counts": {
        "total_papers": 0,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 0
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose PREDNISOLONE for autosomal dominant keratitis-ichthyosis-hearing loss syndrome",
      "drug": {
        "id": "CHEMBL131",
        "name": "PREDNISOLONE",
        "aliases": [
          "Prednisolone sodium phosphate",
          "Prednisolone acetate",
          "Delta-Cortef",
          "Pediapred",
          "Solu-Medrol"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0007850",
        "name": "autosomal dominant keratitis-ichthyosis-hearing loss syndrome",
        "aliases": [
          "keratitis-ichthyosis-hearing loss syndrome, autosomal dominant",
          "AD-KID syndrome",
          "KID syndrome, autosomal dominant",
          "keratitis, ichthyosis, and deafness syndrome, autosomal dominant",
          "keratitis-ichthyosis-deafness syndrome, autosomal dominant"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 0,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 0
      },
      "support_ratio": "No papers retrieved",
      "queries_used": 10,
      "top_papers": []
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Low",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.388,
        "decision": "rerun",
        "dimensions": {
          "completeness": {
            "score": 0.8,
            "reason": "4/5 sections present"
          },
          "evidence_support": {
            "score": 0.0,
            "reason": "No claims generated"
          },
          "citation_validity": {
            "score": 0.0,
            "reason": "0 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/0 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 0.0,
            "reason": "0/0 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "evidence_support",
          "citation_validity",
          "mechanistic_specificity",
          "contradiction_handling",
          "traceability"
        ],
        "rerun_targets": [
          "LiteratureAgent",
          "MechanismAgent",
          "SynthesisCriticAgent"
        ]
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Lack of direct evidence.",
        "Potential for off-target effects of prednisolone given its broad mechanism of action."
      ],
      "limitations": [
        "The analysis is limited by the absence of any retrieved literature.",
        "The current assessment is based solely on the lack of supporting data, not on any negative findings."
      ],
      "missing_data": [
        "Literature evidence linking prednisolone to autosomal dominant keratitis-ichthyosis-hearing loss syndrome.",
        "Mechanistic data on how prednisolone might affect the specific molecular pathways disrupted in this syndrome.",
        "Pre-clinical or clinical data on the efficacy and safety of prednisolone for this condition."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct a thorough literature search using broader keywords related to the syndrome and potential therapeutic targets of prednisolone.",
        "Investigate the known genetic mutations and molecular pathways involved in autosomal dominant keratitis-ichthyosis-hearing loss syndrome to identify potential overlaps with prednisolone's mechanisms of action.",
        "Perform in vitro or in vivo studies to assess the efficacy of prednisolone in relevant models of the syndrome."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 0,
      "claims": []
    },
    "11_provenance_appendix": {
      "total_entries": 0,
      "entries": []
    }
  },
  "metadata": {
    "run_id": "2813a27a08e5",
    "created_at": "2026-06-03T11:55:59.557806+00:00",
    "drug": "PREDNISOLONE",
    "disease": "autosomal dominant keratitis-ichthyosis-hearing loss syndrome",
    "total_claims": 0,
    "quality_score": 0.3875,
    "reruns": 0
  }
}
```
